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Pulmonary Diseases such as Lung Cancer and Chronic Obstructive Pulmonary 
Disease (COPD) are currently the major leading cause of death and its prevelance is 
increasing. The leading cause of COPD is smoking and an estimated 600 million 
patients suffer from the disease. We collected blood plasma from gefitinib-treated 
NSCLC patients in Japan in a pharmacoepidemiologic cohort study. Today, we are able 
to optimise lung retention and correlate drug Pharmaco Kinetics in lung with effect and 
toxicity when only total concentration of drug in lung tissue homogenate can be 
measured [1]. 
Examples will be given from large clinical studies where we have developed 
dedicated protein Biomarker diagnosis technologies in order to discover proteomic 
markers associated with development of acute ILD events, and drug efficacy. In 
addition, targeted Multiple Reaction Monitoring (MRM) multiplex quantitation assay 
developments will be outlined and presented. These current MRM methods were applied 
to biofluid and tissue applications from patients, as well as Biobanking archives. The 
MRM assays platforms as such are generic and can be developed and applied in 
principle to any set of key regulating target proteins within disease [2]. 
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